trending Market Intelligence /marketintelligence/en/news-insights/trending/a6H9G5qw_NioZm2sa6q0iw2 content esgSubNav
In This List

UK drugs association drops legal battle over new cost constraints

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


UK drugs association drops legal battle over new cost constraints

The Association of the British Pharmaceutical Industry's board unanimously agreed to not appeal a high court's decision to turn down its application for a judicial review of the National Institute for Health and Care Excellence's new cost rules for drugs.

Previously, the trade association of biopharmaceutical companies in the U.K. sought to challenge NICE's policy that limits funding of drugs expected to cost the U.K.'s National Health Service more than £20 million per year in any of the first three years of use.

The application was rejected by High Court Honourable Justice Elisabeth Laing.